New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
09:56 EDTCMA, END, LAZ, NFX, RSPP, RGDO, RMD, SBGLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Comerica (CMA) downgraded to Neutral from Buy at Citigroup... Endeavour (END) downgraded to Market Perform from Outperform at FBR Capital... Lazard (LAZ) downgraded to Outperform from Strong Buy at Raymond James... Newfield Exploration (NFX) downgraded to Hold from Buy at Societe Generale... RSP Permian (RSPP) downgraded to Neutral from Buy at UBS... Regado Biosciences (RGDO) downgraded to Underperform from Outperform at Wedbush... ResMed (RMD) downgraded to Hold from Buy at Deutsche Bank... Sibanye Gold (SBGL) downgraded to Sell from Neutral at UBS.
News For CMA;END;LAZ;NFX;RSPP;RGDO;RMD;SBGL From The Last 14 Days
Check below for free stories on CMA;END;LAZ;NFX;RSPP;RGDO;RMD;SBGL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:07 EDTRMDResMed announces findings on SleepMinder device to diagnose SDB
Subscribe for More Information
14:02 EDTRMDResMed announces results of study on cardiac patients with sleep apnoea
Subscribe for More Information
August 27, 2014
07:45 EDTCMASterne Agee to hold a tour
Texas Bank Tour travels throughout Dallas visiting various banks on August 27-29.
August 25, 2014
12:19 EDTRGDOOn The Fly: Midday Wrap
Subscribe for More Information
10:45 EDTRGDORegado Biosciences downgraded to Hold from Buy at Jefferies
Subscribe for More Information
10:00 EDTRGDOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:11 EDTRGDOOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTRGDORegado Biosciences downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
07:46 EDTRGDORegado terminates enrollment in REGULATE-PCI Phase 3 trial
Regado Biosciences announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program, Revolixys Kit. The decision was made based on a recommendation from the trial’s Data and Safety Monitoring Board following their analysis of the data from the first approximately 3250 patients enrolled in what was intended to be a 13,200-patient trial comparing the safety and efficacy of Revolixys Kit with bivalirudin. The company said, “The DSMB indicated that the level of serious allergic adverse events associated with Revolixys was of a frequency and severity such that they recommended that we do not enroll any further patients in the REGULATE-PCI trial. We will now undertake a complete review of the unblinded database from REGULATE-PCI, which we expect will take several months to complete."
August 24, 2014
13:51 EDTRMDResMed wins initial decision in ITC patent infringement action
Subscribe for More Information
August 22, 2014
18:46 EDTRMDITC Judge issues mixed decision in ResMed case
Subscribe for More Information
August 21, 2014
10:14 EDTLAZOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:45 EDTNFXNewfield Exploration management to meet with UBS
Subscribe for More Information
08:12 EDTLAZLazard upgraded at Buckingham
Subscribe for More Information
08:01 EDTLAZLazard upgraded to Buy from Neutral at Buckingham

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use